Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair

被引：167

作者：

Lu, Yanxin ^{[1
]}

Kwintkiewicz, Jakub ^{[2
,3
]}

Liu, Yang ^{[1
]}

Tech, Katherine ^{[4
]}

Frady, Lauren N. ^{[2
,3
]}

Su, Yu-Ting ^{[1
]}

Bautista, Wendy ^{[1
]}

Moon, Seog In ^{[1
]}

MacDonald, Jeffrey ^{[4
]}

Ewend, Matthew G. ^{[2
,3
]}

Gilbert, Mark R. ^{[1
]}

Yang, Chunzhang ^{[1
]}

Wu, Jing ^{[1
,2
,3
]}

机构：

[1] NCI, Neurooncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA

[2] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[3] Univ North Carolina Chapel Hill, Dept Neurosurg, Chapel Hill, NC USA

[4] Univ North Carolina Chapel Hill, Sch Med, Dept Biomed Engn, Chapel Hill, NC USA

来源：

CANCER RESEARCH | 2017年 / 77卷 / 07期

关键词：

MUTANT IDH1; ISOCITRATE DEHYDROGENASE; OLIGODENDROGLIAL TUMORS; ADJUVANT TEMOZOLOMIDE; GLIOBLASTOMA CELLS; PHASE-III; MUTATIONS; CANCER; INHIBITOR; SURVIVAL;

D O I：

10.1158/0008-5472.CAN-16-2773

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mutations in isocitrate dehydrogenase (IDH) are the most prevalent genetic abnormalities in lower grade gliomas. The presence of these mutations in glioma is prognostic for better clinical outcomes with longer patient survival. In the present study, we found that defects in oxidative metabolism and 2-HG production confer chemosensitization in IDH1-mutated glioma cells. In addition, temozolomide (TMZ) treatment induced greater DNA damage and apoptotic changes in mutant glioma cells. The PARP1-associated DNA repair pathway was extensively compromised in mutant cells due to decreased NAD_ availability. Targeting the PARP DNA repair pathway extensively sensitized IDH1-mutated glioma cells to TMZ. Our findings demonstrate a novel molecular mechanism that defines chemosensitivity in IDH-mutated gliomas. Targeting PARP-associated DNA repair may represent a novel therapeutic strategy for gliomas.

引用

页码：1709 / 1718

页数：10

共 50 条

[1] Blockade of Glutathione Metabolism in IDH1-Mutated Glioma
Tang, Xiaoying
Fu, Xiao
Liu, Yang
Yu, Di
Cai, Sabrina J.
Yang, Chunzhang
MOLECULAR CANCER THERAPEUTICS, 2020, 19 (01) : 221 - 230
[2] Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Karpel-Massler, Georg
Ishida, Chiaki Tsuge
Bianchetti, Elena
Zhang, Yiru
Shu, Chang
Tsujiuchi, Takashi
Banu, Matei A.
Garcia, Franklin
Roth, Kevin A.
Bruce, Jeffrey N.
Canoll, Peter
Siegelin, Markus D.
NATURE COMMUNICATIONS, 2017, 8
[3] IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Eduardo Megias-Vericat, Juan
Ballesta-Lopez, Octavio
Barragan, Eva
Montesinos, Pau
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2019, 9 : 19 - 32
[4] An IDH1-mutated primary gliosarcoma: case report
Hsieh, Jason K.
Hong, Christopher S.
Manjila, Sunil
Cohen, Mark L.
Lo, Simon
Rogers, Lisa
Sloan, Andrew E.
JOURNAL OF NEUROSURGERY, 2017, 126 (02) : 476 - 480
[5] Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, Genglin
Reitman, Zachary J.
Duncan, Christopher G.
Spasojevic, Ivan
Gooden, David M.
Rasheed, B. Ahmed
Yang, Rui
Lopez, Giselle Y.
He, Yiping
McLendon, Roger E.
Bigner, Darell D.
Yan, Hai
CANCER RESEARCH, 2013, 73 (02) : 496 - 501
[6] Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas
Elkhaled, Adam
Jalbert, Llewellyn E.
Phillips, Joanna J.
Yoshihara, Hikari A. I.
Parvataneni, Rupa
Srinivasan, Radhika
Bourne, Gabriela
Berger, Mitchel S.
Chang, Susan M.
Cha, Soonmee
Nelson, Sarah J.
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (116)
[7] Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
DiNardo, C. D.
Stein, E. M.
de Botton, S.
Roboz, G. J.
Altman, J. K.
Mims, A. S.
Swords, R.
Collins, R. H.
Mannis, G. N.
Pollyea, D. A.
Donnellan, W.
Fathi, A. T.
Pigneux, A.
Erba, H. P.
Prince, G. T.
Stein, A. S.
Uy, G. L.
Foran, J. M.
Traer, E.
Stuart, R. K.
Arellano, M. L.
Slack, J. L.
Sekeres, M. A.
Willekens, C.
Choe, S.
Wang, H.
Zhang, V.
Yen, K. E.
Kapsalis, S. M.
Yang, H.
Dai, D.
Fan, B.
Goldwasser, M.
Liu, H.
Agresta, S.
Wu, B.
Attar, E. C.
Tallman, M. S.
Stone, R. M.
Kantarjian, H. M.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) : 2386 - 2398
[8] Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1-Mutated Cancer Cells
Khurshed, Mohammed
Prades-Sagarra, Elia
Saleh, Sarah
Sminia, Peter
Wilmink, Johanna W.
Molenaar, Remco J.
Crezee, Hans
van Noorden, Cornelis J. F.
CANCERS, 2022, 14 (24)
[9] A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors
Khurshed, Mohammed
Molenaar, Remco J.
van Linde, Myra E.
Mathot, Ron A.
Struys, Eduard A.
van Wezel, Tom
van Noorden, Cornelis J. F.
Kluempen, Heinz-Josef
Bovee, Judith V. M. G.
Wilmink, Johanna W.
CANCERS, 2021, 13 (10)
[10] A perioperative study of Safusidenib in patients with IDH1-mutated glioma
Cain, Sarah A.
Topp, Monique
Rosenthal, Mark
Tobler, Robert
Freytag, Saskia
Best, Sarah A.
Whittle, James R.
Drummond, Katharine J.
FUTURE ONCOLOGY, 2024, 20 (33) : 2533 - 2545

← 1 2 3 4 5 →